Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PPL022
MIFTS: 54

Papilloma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Papilloma

About this section

MalaCards integrated aliases for Papilloma:

Name: Papilloma 12 54 15 71
Papillomatosis 12 54 15 71

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2615
MeSH 43 D010212
NCIt 49 C3713 C7440
SNOMED-CT 67 711329002
UMLS 71 C0030354 C0205875
Sources

Summaries for Papilloma

About this section
Disease Ontology : 12 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to squamous cell papilloma and inverted papilloma. An important gene associated with Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Metformin and Bethanechol have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and cervix, and related phenotypes are Decreased human papilloma virus 16 (HPV16) pseudovirus infection and growth/size/body region

Wikipedia : 74 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Sources

Related Diseases for Papilloma

About this section

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1092)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 35.0 TP53 KRT14 CDKN2A
2 inverted papilloma 34.6 TP53 KRT5 KRT20 KRT13 CDKN2A
3 bladder transitional cell papilloma 34.6 TP53 KRT20 CDKN1A
4 urinary bladder inverted papilloma 34.5 RB1 CDKN2A
5 inverted transitional papilloma 34.4 KRT5 CDKN2A
6 subareolar duct papillomatosis 34.4 KRT8 KRT5
7 frontal sinus inverted papilloma 34.4 KRT5 KRT13
8 skin papilloma 34.0 TP53 PTEN KRT14 KRT10 CDKN1A
9 anogenital venereal wart 33.3 UBE3A TP53 CDKN2A
10 oral cancer 33.3 TP53 KRT13 CDKN2A
11 penile cancer 33.2 UBE3A TP53 PTEN CDKN2A
12 keratosis, seborrheic 32.5 TP53 KRT5 KRT10 IVL CDKN2A
13 palmoplantar keratoderma, epidermolytic 32.5 KRT5 KRT14 KRT10 FLG
14 li-fraumeni syndrome 32.4 TP53 RB1 PTEN IGF2 CDKN2A CDKN1A
15 cervix uteri carcinoma in situ 32.1 TP53 RB1 CDKN2A
16 suppressor of tumorigenicity 3 31.9 UBE3A TP53 RB1 CDKN2A CDKN1A
17 cervical intraepithelial neoplasia 31.9 KRT8 IVL CDKN2A
18 in situ carcinoma 31.5 TP53 PTEN KRT8 KRT5 KRT14 CDKN2A
19 anus cancer 31.5 UBE3A TP53 CDKN2A
20 transitional cell carcinoma 31.5 TP53 PTEN KRT8 KRT20 CDKN2A CDKN1A
21 cervical cancer 31.5 UBE3A TP53 RB1 PTEN KRT14 KRT10
22 oropharynx cancer 31.4 UBE3A TP53 KRT5 KRT14 CDKN2A
23 familial retinoblastoma 31.4 TP53 RB1 CDKN2A
24 squamous cell carcinoma 31.3 TP53 RB1 PTEN KRT14 KRT13 IVL
25 adenocarcinoma 31.3 TP53 RB1 PTEN KRT20 CDKN2A CDKN1A
26 epidermodysplasia verruciformis 1 31.2 UBE3A TP53 KRT14
27 retinoblastoma 31.2 TYMS TP53 RB1 CDKN2A CDKN1A
28 ductal carcinoma in situ 31.2 TP53 PTEN KRT8 KRT5 KRT14 CDKN2A
29 vulvar intraepithelial neoplasia 31.2 TP53 CDKN2A
30 esophagitis 31.2 TP53 IVL IL4 CDKN2A
31 verrucous carcinoma 31.1 TP53 PTEN KRT5 KRT10 CDKN2A
32 bowenoid papulosis 31.1 FLG CDKN2A
33 meningioma, familial 31.0 TP53 PTEN IGF2 CDKN2A AMOT
34 vaginal cancer 31.0 UBE3A TP53 CDKN2A
35 actinic keratosis 31.0 TP53 KRT20 FLG CDKN2A
36 papillary transitional carcinoma 31.0 TP53 KRT20
37 keratosis 31.0 TP53 KRT5 KRT10 IVL FLG CDKN2A
38 skin carcinoma 31.0 TP53 KRT8 KRT20 IVL FLG CDKN2A
39 nasopharyngeal carcinoma 31.0 TP53 PTEN KRT13 CDKN2A CDKN1A
40 glandular cystitis 31.0 TP53 KRT20 KRT13
41 villous adenoma 30.9 TP53 KRT8 KRT20
42 breast fibroadenoma 30.9 TP53 KRT8 KRT14
43 bladder cancer 30.9 TYMS TP53 RB1 PTEN KRT8 KRT20
44 teratoma 30.9 TP53 PTEN KRT20 CDKN2A
45 small cell carcinoma 30.9 TP53 PTEN KRT8 KRT20 CDKN2A
46 esophageal cancer 30.9 TYMS TP53 RB1 PTEN IL4 IGF2
47 vulva cancer 30.9 TP53 KRT13 CDKN2A
48 intrahepatic cholangiocarcinoma 30.9 TP53 PTEN KRT20
49 carcinosarcoma 30.8 TP53 PTEN CDKN2A
50 ameloblastoma 30.8 TP53 KRT8 KRT14

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma
Sources

Symptoms & Phenotypes for Papilloma

About this section

GenomeRNAi Phenotypes related to Papilloma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 9.17 AMOT CDKN2A IFNAR1 IGF2 IL4 KRT8

MGI Mouse Phenotypes related to Papilloma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.32 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
2 cellular MP:0005384 10.29 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
3 cardiovascular system MP:0005385 10.26 AMOT CDKN1A CDKN2A IFNAR1 IGF2 KRT8
4 digestive/alimentary MP:0005381 10.26 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
5 mortality/aging MP:0010768 10.25 AMOT CDKN1A CDKN2A IFNAR1 IGF2 IL4
6 integument MP:0010771 10.2 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
7 endocrine/exocrine gland MP:0005379 10.19 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
8 embryo MP:0005380 10.16 AMOT CDKN1A CDKN2A IGF2 KRT8 PTEN
9 liver/biliary system MP:0005370 10.09 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT8
10 craniofacial MP:0005382 10.08 CDKN1A IGF2 IL4 KRT14 KRT5 RB1
11 no phenotypic analysis MP:0003012 9.92 CDKN1A CDKN2A IFNAR1 IGF2 IL4 RB1
12 neoplasm MP:0002006 9.91 CDKN1A CDKN2A IFNAR1 KRT14 PTEN RB1
13 reproductive system MP:0005389 9.9 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
14 pigmentation MP:0001186 9.65 CDKN2A KRT14 PTEN RB1 TP53
15 respiratory system MP:0005388 9.56 CDKN1A CDKN2A IGF2 IL4 KRT14 PTEN
16 vision/eye MP:0005391 9.28 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT14
Sources

Drugs & Therapeutics for Papilloma

About this section

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Bethanechol Approved Phase 4 674-38-4 2370
3
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
4
Cidofovir Approved Phase 4 113852-37-2 60613
5
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
6
Polihexanide Approved, Investigational Phase 4 28757-47-3
7
Cantharidin Approved, Investigational Phase 4 56-25-7
8
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
9
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
10
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
11
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
12
Dolutegravir Approved Phase 4 1051375-16-6 54726191
13
BCG vaccine Investigational Phase 4
14
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
15 Muscarinic Agonists Phase 4
16 Anti-Bacterial Agents Phase 4
17 Antibiotics, Antitubercular Phase 4
18 Insulin, Globin Zinc Phase 4
19 insulin Phase 4
20 Hypoglycemic Agents Phase 4
21 Chlorhexidine gluconate Phase 4
22 Anti-Infective Agents, Local Phase 4
23 Disinfectants Phase 4
24 Biguanides Phase 4
25 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
26 MF59 oil emulsion Phase 4
27 Pharmaceutical Solutions Phase 4
28 Anti-Infective Agents Phase 4
29 Antiviral Agents Phase 4
30 Vaccines Phase 4
31 Anti-Retroviral Agents Phase 4
32
protease inhibitors Phase 4
33 Anti-HIV Agents Phase 4
34 HIV Protease Inhibitors Phase 4
35 Cytochrome P-450 Enzyme Inhibitors Phase 4
36 Integrase Inhibitors Phase 4
37 HIV Integrase Inhibitors Phase 4
38 Cytochrome P-450 CYP3A Inhibitors Phase 4
39
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
40
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
41
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
42
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
43
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
44
Azithromycin Approved Phase 3 83905-01-5 447043 55185
45
Promethazine Approved, Investigational Phase 3 60-87-7 4927
46
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
47
Histamine Approved, Investigational Phase 3 51-45-6 774
48
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
49
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
50
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 502)
# Name Status NCT ID Phase Drugs
1 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
2 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
3 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Unknown status NCT01101750 Phase 4
4 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
5 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
6 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
7 A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines Completed NCT00956553 Phase 4
8 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
9 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
10 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
11 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
12 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
13 Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination Completed NCT02225327 Phase 4
14 Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
15 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
16 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
17 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
18 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
19 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Recruiting NCT03391921 Phase 4
20 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Active, not recruiting NCT03180034 Phase 4
21 Immunogenicity, Compliance, Knowledge and Attitudes in Postpartum Women During a Two Dose 9-valent HPV Vaccination Series Not yet recruiting NCT04311528 Phase 4
22 A Pilot Study of the Immunogenicity of a Two-dose Protocol for 9-valent Human Papilloma Virus Vaccination in Postpartum Girls and Women (15-45 Years Old) Previously Unvaccinated Against HPV Not yet recruiting NCT04274153 Phase 4
23 Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections. Not yet recruiting NCT04232917 Phase 4 2LPAPI®;Placebo
24 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
25 A Multicenter, Randomized, Open-label Trial to Establish Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV Not yet recruiting NCT04265950 Phase 4
26 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
27 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
28 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
29 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
30 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
31 Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions Unknown status NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
32 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Unknown status NCT03296397 Phase 3
33 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
34 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
35 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
36 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
37 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
38 Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India Completed NCT00380367 Phase 3
39 An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea Completed NCT00157950 Phase 3
40 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
41 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
42 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
43 A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls Completed NCT01254643 Phase 3
44 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
45 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
46 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
47 Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process Completed NCT00169494 Phase 3
48 A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study). Completed NCT00092547 Phase 3
49 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
50 Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years) Completed NCT00196924 Phase 3

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


podophyllin
PODOPHYLLIN PWDR
Sources

Genetic Tests for Papilloma

About this section
Sources

Anatomical Context for Papilloma

About this section

MalaCards organs/tissues related to Papilloma:

40
Breast, Skin, Cervix, Testes, Lung, T Cells, Brain
Sources

Publications for Papilloma

About this section

Articles related to Papilloma:

(show top 50) (show all 16882)
# Title Authors PMID Year
1
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 61 54
20395210 2010
2
No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. 61 54
19621447 2009
3
Colonic adenoma with squamous metaplasia. 54 61
18701516 2009
4
Expression of p14ARF, p16INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours. 61 54
18681909 2009
5
Human papilloma virus type16 E6 deregulates CHK1 and sensitizes human fibroblasts to environmental carcinogens independently of its effect on p53. 61 54
19411857 2009
6
FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. 54 61
19287463 2009
7
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. 61 54
19060248 2009
8
Primary adenosquamous carcinoma of the colon: report of five cases. 61 54
19562453 2009
9
Identification of human papillomavirus in esophageal squamous papillomas. 54 61
19084918 2008
10
Staining characteristics of p16INK4a: is there a correlation with lesion grade or high-risk human papilloma virus positivity? 54 61
18958930 2008
11
Re: Paula M.J. Moonen, Judith M.J.E. Bakkers, Lambertus A.L.M. Kiemenay et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007;52:464-9. 61 54
17920185 2008
12
Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. 61 54
18300235 2008
13
Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection. 54 61
19516893 2008
14
On the mechanism of phenotypic conversion of human cervical adenocarcinoma HeLa cells surviving infection by influenza B virus: potential implications for biological management of adenocarcinomas. 54 61
18291599 2008
15
[Efficacy of local use of recombinant interferon alpha-2 preparations in combined treatment of recurrent respiratory papillomatosis]. 61 54
18833124 2008
16
Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. 61 54
18180113 2008
17
Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. 61 54
17855174 2007
18
Overexpression of p27kip1 in urinary bladder urothelial carcinoma. 54 61
18036045 2007
19
Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. 61 54
17977825 2007
20
Carotenoids suppress proliferating cell nuclear antigen and cyclin D1 expression in oral carcinogenic models. 61 54
17369034 2007
21
Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. 61 54
17638654 2007
22
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. 61 54
17116360 2007
23
The expression of p16 (INK4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins. 54 61
17367326 2007
24
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. 54 61
17551924 2007
25
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. 54 61
17294450 2007
26
Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. 54 61
17847937 2007
27
A novel mutation of PTEN gene in a patient with Cowden syndrome with excessive papillomatosis of the lips, discrete cutaneous lesions, and gastrointestinal polyposis. 54 61
17489063 2007
28
Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP). 54 61
17131388 2007
29
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]. 54 61
17685229 2007
30
[Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia]. 61 54
17545048 2007
31
Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. 61 54
17414102 2007
32
Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. 54 61
17295644 2007
33
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. 54 61
16698948 2007
34
Increased expression of fascin associated with malignant transformation of sinonasal inverted papilloma. 61 54
17376306 2007
35
Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis. 54 61
17277618 2007
36
The history of the angiogenic switch concept. 54 61
16990761 2007
37
[Risk factors and clinical characteristic patients with vulvar cancer]. 54 61
17373116 2006
38
Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. 54 61
16965327 2006
39
Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. 54 61
16624261 2006
40
Relationship between cyclin G1 and human papilloma virus infection in cervical intraepithelial neoplasia and cervical carcinoma. 54 61
16845792 2006
41
Relationship between p21 and p53 expression, human papilloma virus infection and malignant transformation in sinonasal-inverted papilloma. 54 61
16703747 2006
42
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice. 54 61
16624193 2006
43
E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway. 54 61
16205640 2006
44
Cell cycle regulatory protein expression profiles by adenovirus p53 infection in human papilloma virus-associated cervical cancer cells. 54 61
19771278 2006
45
Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. 54 61
16979303 2006
46
Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. 61 54
16998598 2006
47
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. 61 54
17310826 2006
48
The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms. 61 54
16142387 2005
49
Markers of malignant transformation of sinonasal inverted papilloma. 61 54
16005600 2005
50
Immunohistochemical evaluation of intermediate filament proteins in squamous papilloma and oral verrucous carcinoma. 54 61
16120114 2005
Sources

Variations for Papilloma

About this section
Sources

Expression for Papilloma

About this section
Search GEO for disease gene expression data for Papilloma.
Sources

Pathways for Papilloma

About this section

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 65
Show member pathways
 13.47 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10
2
Endometrial cancer 36
Show member pathways
 12.83 TP53 RB1 PTEN CDKN2A CDKN1A
3
PI3K-Akt signaling pathway 36
Show member pathways
 12.81 UBE3A TP53 RB1 PTEN IL4 IGF2
4
Gastric cancer 36
Show member pathways
 12.75 TP53 RB1 PTEN IGF2 CDKN2A CDKN1A
5
Glioma 36
Show member pathways
 12.64 TP53 RB1 PTEN CDKN2A CDKN1A
6
Mitotic G1-G1/S phases 65
Show member pathways
 12.55 TYMS TP53 RB1 CDKN2A CDKN1A
7
DNA Damage 4
12.5 TYMS TP53 RB1 CDKN2A CDKN1A
8
Pathways in cancer 36
12.48 TP53 RB1 PTEN IL4 IGF2 IFNAR1
9
Cytoskeletal Signaling 4
12.42 KRT8 KRT5 KRT20 KRT13 KRT10 AMOT
10
Development IGF-1 receptor signaling 22
Show member pathways
 12.39 TP53 PTEN IL4 IGF2 CDKN1A
11
DNA Damage Response 1
Show member pathways
 12.36 TP53 RB1 PTEN CDKN2A CDKN1A
12
Cell cycle 36 1
12.34 TP53 RB1 CDKN2A CDKN1A
13
Cyclins and Cell Cycle Regulation 63
Show member pathways
 12.32 TP53 RB1 CDKN2A CDKN1A
15
Human T-cell leukemia virus 1 infection 36
12.27 TP53 RB1 PTEN CDKN2A CDKN1A
16
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.25 TP53 RB1 IL4 IGF2 IFNAR1
17
Viral carcinogenesis 36
12.23 UBE3A TP53 RB1 CDKN2A CDKN1A
18
p53 Signaling 63
Show member pathways
 12.22 TP53 RB1 PTEN CDKN1A
19
Cellular senescence (KEGG) 36
12.07 TP53 RB1 PTEN CDKN2A CDKN1A
20
Direct p53 effectors 1
12.05 TP53 RB1 PTEN CDKN1A
21
DNA Damage Response (only ATM dependent) 1
11.98 TP53 PTEN CDKN2A CDKN1A
22
Cytoskeleton remodeling Neurofilaments 22
Show member pathways
 11.95 KRT8 KRT5 KRT14 KRT13
23
Staphylococcus aureus infection 36
11.88 KRT20 KRT14 KRT13 KRT10
24
Small cell lung cancer 36
11.85 TP53 RB1 PTEN CDKN1A
25
Androgen receptor signaling pathway 1
11.84 UBE3A RB1 PTEN CDKN1A
26
Retinoblastoma (RB) in Cancer 1
11.79 TYMS TP53 RB1 CDKN1A
27
Senescence and Autophagy in Cancer 1
11.74 TP53 RB1 PTEN CDKN2A CDKN1A
28
Platinum drug resistance 36
11.71 TP53 CDKN2A CDKN1A
29
E2F transcription factor network 1
11.71 TYMS RB1 CDKN1A
30
Keratinization 65
Show member pathways
 11.68 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10
31
Bladder cancer 36 1
11.67 TP53 RB1 CDKN2A CDKN1A
32
Transcription_P53 signaling pathway 22
11.63 UBE3A TP53 RB1 CDKN2A CDKN1A
33
Glucocorticoid receptor regulatory network 1
11.57 TP53 KRT5 KRT14 IL4 CDKN1A
34
Glioblastoma Multiforme 63
11.48 TP53 RB1 PTEN IGF2 CDKN2A CDKN1A
35
Photodynamic therapy-induced AP-1 survival signaling. 1
11.44 TP53 RB1 CDKN2A CDKN1A
36
Integrated Cancer Pathway 1
11.37 TP53 RB1 PTEN CDKN1A
37
TP53 Network 1
Show member pathways
 11.09 TP53 CDKN2A CDKN1A
38
Inhibition of Ribosome Biogenesis by p14(ARF) 63
11.08 TP53 RB1 CDKN2A
39
LncRNA-mediated mechanisms of therapeutic resistance 1
10.76 TP53 CDKN1A
40
Transcriptional activation of p53 responsive genes 65
Show member pathways
 10.57 TP53 CDKN1A
Sources

GO Terms for Papilloma

About this section

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.17 UBE3A UBE2L3 TYMS TP53 RB1 PTEN
2 cytosol GO:0005829 9.86 UBE3A UBE2L3 TYMS TP53 PTEN KRT8
3 keratin filament GO:0045095 9.46 KRT8 KRT5 KRT14 KRT13
4 cornified envelope GO:0001533 9.43 KRT10 IVL FLG
5 intermediate filament GO:0005882 9.17 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.97 TP53 RB1 PTEN CDKN2A CDKN1A
2 protein stabilization GO:0050821 9.84 TP53 PTEN CDKN2A CDKN1A
3 regulation of cell cycle GO:0051726 9.8 TP53 RB1 PTEN CDKN1A
4 cell cycle arrest GO:0007050 9.76 TP53 RB1 CDKN2A CDKN1A
5 negative regulation of cell growth GO:0030308 9.73 TP53 RB1 CDKN2A CDKN1A
6 keratinocyte differentiation GO:0030216 9.7 KRT10 IVL FLG
7 Ras protein signal transduction GO:0007265 9.62 TP53 RB1 CDKN2A CDKN1A
8 response to arsenic-containing substance GO:0046685 9.59 PTEN CDKN1A
9 hemidesmosome assembly GO:0031581 9.58 KRT5 KRT14
10 hepatocyte apoptotic process GO:0097284 9.58 RB1 KRT8
11 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.58 PTEN CDKN2A CDKN1A
12 prostate gland growth GO:0060736 9.56 UBE3A PTEN
13 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.56 RB1 PTEN CDKN2A CDKN1A
14 negative regulation of dendritic spine morphogenesis GO:0061002 9.55 UBE3A PTEN
15 peptide cross-linking GO:0018149 9.54 KRT10 IVL FLG
16 signal transduction by p53 class mediator GO:0072331 9.51 TP53 CDKN1A
17 keratinization GO:0031424 9.5 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10
18 intestinal epithelial cell maturation GO:0060574 9.48 TYMS CDKN1A
19 replicative senescence GO:0090399 9.33 TP53 CDKN2A CDKN1A
20 cornification GO:0070268 9.23 KRT8 KRT5 KRT20 KRT14 KRT13 KRT10

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 UBE3A UBE2L3 TP53 RB1 PTEN KRT8
2 disordered domain specific binding GO:0097718 9.33 TP53 RB1 CDKN2A
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2A CDKN1A
4 structural molecule activity GO:0005198 9.02 KRT20 KRT14 KRT13 KRT10 FLG
Sources

Sources for Papilloma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....